Area of research
Public Health, Environmental and Occupational Health · Computational Theory and Mathematics
Research interest
Research interests include Malaria Research and Control, Computational Drug Discovery Methods, Mosquito-borne diseases and control, and HIV/AIDS drug development and treatment.
Identification of Compound <b>15</b> (MMV1581361) as a <i>Pf</i>ATP4 Inhibitor with Transmission-Blocking Activity and <i>In Vivo</i> Efficacy in a SCID Mouse Model of Malaria.
In vivo screen of Plasmodium targets for mosquito-based malaria control.
In vivo screen of Plasmodium targets for mosquito-based malaria control
<i>Anopheles</i> mosquito survival and pharmacokinetic modeling show the mosquitocidal activity of nitisinone.
Screening of Medicines for Malaria Venture Open Boxes Identifies Potent SARS-CoV‑2 Papain-like Protease (PL<sup>pro</sup>) Inhibitors.
Characterizing the quick-killing mechanism of action of azithromycin analogs against malaria parasites
CRISPR/Cas9-engineering of Kell null erythrocytes to unveil host targeted irresistible antimalarial.
Identifying a next-generation antimalarial trioxolane in a landscape of artemisinin partial resistance.
Combating antimicrobial resistance in malaria, HIV and tuberculosis
Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase.
Tambjamines as Fast-Acting Multistage Antimalarials
Tambjamines as Fast-Acting Multistage Antimalarials.
Global Health Priority Box─Proactive Pandemic Preparedness.
Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission
Inhibitors of malaria parasite cyclic nucleotide phosphodiesterases block asexual blood-stage development and mosquito transmission.
A Prodrug Strategy to Reposition Atovaquone as a Long-Acting Injectable for Malaria Chemoprotection
Optimization of diastereomeric dihydropyridines as antimalarials
Author Correction: Antimalarial drug discovery: progress and approaches.
CRISPR/Cas9-engineering of Kell null erythrocytes to unveil host targeted irresistible antimalarial
Antimalarial drug discovery: progress and approaches
Antimalarial drug discovery: progress and approaches.
Safe and effective treatments are needed for cryptosporidiosis, a truly neglected tropical disease.
The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of <i>Plasmodium falciparum</i> Viability after Antimalarial Treatment In Vitro.
Development and application of a PBPK modeling strategy to support antimalarial drug development.
MAIP: An Open-Source Tool to Enrich High-Throughput Screening Output and Identify Novel, Druglike Molecules with Antimalarial Activity.
Discovery of 1,3,4-oxadiazoles with slow-action activity against <i>Plasmodium falciparum</i> malaria parasites
Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase
Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.
Discovery and Characterization of Potent, Efficacious, Orally Available Antimalarial Plasmepsin X Inhibitors and Preclinical Safety Assessment of <b>UCB7362</b>.
The Antifungal Itraconazole Is a Potent Inhibitor of Chikungunya Virus Replication.